(MedPage Today) — DENVER — A sustained-release VEGF inhibitor implant outperformed standard anti-VEGF therapy for maintaining visual acuity in neovascular, or wet, age-related macular degeneration (AMD), showed a randomized trial reported here…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.






